Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease

[1]  Noelia Geribaldi-Doldán,et al.  Altered regulation of the Spry2/Dyrk1A/PP2A triad by homocysteine impairs neural progenitor cell proliferation. , 2016, Biochimica et biophysica acta.

[2]  Tom Eichele,et al.  Regularized Linear Discriminant Analysis of EEG Features in Dementia Patients , 2016, Front. Aging Neurosci..

[3]  A. Smith,et al.  Homocysteine, B Vitamins, and Cognitive Impairment. , 2016, Annual review of nutrition.

[4]  Y. H. Kwon,et al.  Homocysteine induces PUMA-mediated mitochondrial apoptosis in SH-SY5Y cells , 2016, Amino Acids.

[5]  Hector H. Huang,et al.  Phosphorylation of β-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis , 2016, Neuron.

[6]  Maria V. Sanchez-Vives,et al.  Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex , 2016, The Journal of Neuroscience.

[7]  G. Aghajanian,et al.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants , 2016, Nature Medicine.

[8]  R. Xavier,et al.  The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells , 2015, eLife.

[9]  Jianhua Shi,et al.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I , 2015, The Journal of Biological Chemistry.

[10]  Y. Yanagawa,et al.  Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage , 2014, Neurobiology of Disease.

[11]  B. Dubois,et al.  Plasma DYRK1A as a novel risk factor for Alzheimer's disease , 2014, Translational Psychiatry.

[12]  Z. Fišar,et al.  GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  J. Delabar,et al.  A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase. , 2014, Analytical biochemistry.

[14]  J. Delabar,et al.  Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain , 2013, Journal of Molecular Neuroscience.

[15]  L. Siever,et al.  Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients , 2012, Psychiatry Research.

[16]  J. Delabar,et al.  Dyrk1A, a Serine/Threonine Kinase, is Involved in ERK and Akt Activation in the Brain of Hyperhomocysteinemic Mice , 2012, Molecular Neurobiology.

[17]  B. V. van Bon,et al.  BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients , 2012, Molecular Neurobiology.

[18]  L. Monteggia,et al.  Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders , 2012, Pharmacological Reviews.

[19]  Y. Hérault,et al.  DYRK1A: A master regulatory protein controlling brain growth , 2012, Neurobiology of Disease.

[20]  D. Matsuzawa,et al.  Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  A. Malafosse,et al.  Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism , 2011, Brain and behavior.

[22]  B. Diniz,et al.  Brain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond , 2011, NeuroMolecular Medicine.

[23]  Hua Lu,et al.  p53 downregulates Down syndrome‐associated DYRK1A through miR‐1246 , 2011, EMBO reports.

[24]  D. Wald,et al.  Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants , 2011, Alzheimer's & Dementia.

[25]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[27]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[28]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[29]  C. Björkelund,et al.  Midlife homocysteine and late-life dementia in women. A prospective population study , 2011, Neurobiology of Aging.

[30]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[31]  B. Han,et al.  REST Regulates DYRK1A Transcription in a Negative Feedback Loop* , 2011, The Journal of Biological Chemistry.

[32]  M. Dierssen,et al.  Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations , 2010, Neurobiology of Disease.

[33]  O. Forlenza,et al.  Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[34]  Y. Hérault,et al.  DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase , 2009, PloS one.

[35]  Hong-Hee Kim,et al.  Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis* , 2009, The Journal of Biological Chemistry.

[36]  J. Delabar,et al.  Calpain activation is required for homocysteine-mediated hepatic degradation of inhibitor I kappa B alpha. , 2009, Molecular genetics and metabolism.

[37]  Desmond J. Smith,et al.  Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.

[38]  J. Delabar,et al.  Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice. , 2009, Biochemical and biophysical research communications.

[39]  Tuomo Hänninen,et al.  BDNF is a novel marker of cognitive function in ageing women: The DR’s EXTRA Study , 2008, Neurobiology of Learning and Memory.

[40]  K. Christian,et al.  BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory? , 2008, Neurobiology of Learning and Memory.

[41]  J. Drai,et al.  Methods for homocysteine analysis and biological relevance of the results. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  X. Estivill,et al.  Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice , 2002, Molecular and Cellular Biology.

[43]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[44]  E. Tolosa,et al.  BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. , 1999, Journal of neuropathology and experimental neurology.

[45]  E. Ezan,et al.  Enzyme immunometric assay for leukotriene C4. , 1994, Journal of immunological methods.

[46]  Steven A. Johnson,et al.  BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.

[47]  J. Grassi,et al.  Production of monoclonal antibodies against interleukin-1α and -1β: Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media , 1989 .

[48]  P. Thomas,et al.  A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. , 1987, Journal of immunological methods.

[49]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[50]  A. Drzezga,et al.  The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. , 2013, Current Alzheimer research.

[51]  David Touboul,et al.  Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients , 2012, Acta Neuropathologica.

[52]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[53]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.